Chenlin Feng, Jasper F Ooms, Erik H J Danen, Laura H Heitman
{"title":"GPCR-G protein signalling and its mutational landscape in cancer-Driver or passenger.","authors":"Chenlin Feng, Jasper F Ooms, Erik H J Danen, Laura H Heitman","doi":"10.1111/bph.70102","DOIUrl":null,"url":null,"abstract":"<p><p>G protein-coupled receptors (GPCRs) play a crucial role in cellular signalling, regulating various physiological processes. Abnormal expression and mutations of GPCRs have been implicated in several types of cancer, influencing tumour initiation, progression and immune response. In this review, we present an overview of recent research on GPCR involvement in cancer and discuss the evidence supporting whether mutations in GPCRs act as cancer driver or passenger. Accumulation of GPCR mutations in some highly conserved structural motifs and the mutually exclusiveness observed between G<sub>i</sub>-coupled GPCRs and G protein subunit alpha S (GNAS)-activating mutations indicate their potential driving role in cancer. However, the functional redundancy of GPCR signalling networks together with the widespread but low frequency distribution of GPCR mutations indicate that they may rather act as passengers. The future of GPCR drug discovery hinges on overcoming challenges related to data availability and the integration of GPCR research with broader cancer studies using multiomics approaches.</p>","PeriodicalId":9262,"journal":{"name":"British Journal of Pharmacology","volume":" ","pages":""},"PeriodicalIF":6.8000,"publicationDate":"2025-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"British Journal of Pharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/bph.70102","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0
Abstract
G protein-coupled receptors (GPCRs) play a crucial role in cellular signalling, regulating various physiological processes. Abnormal expression and mutations of GPCRs have been implicated in several types of cancer, influencing tumour initiation, progression and immune response. In this review, we present an overview of recent research on GPCR involvement in cancer and discuss the evidence supporting whether mutations in GPCRs act as cancer driver or passenger. Accumulation of GPCR mutations in some highly conserved structural motifs and the mutually exclusiveness observed between Gi-coupled GPCRs and G protein subunit alpha S (GNAS)-activating mutations indicate their potential driving role in cancer. However, the functional redundancy of GPCR signalling networks together with the widespread but low frequency distribution of GPCR mutations indicate that they may rather act as passengers. The future of GPCR drug discovery hinges on overcoming challenges related to data availability and the integration of GPCR research with broader cancer studies using multiomics approaches.
G蛋白偶联受体(gpcr)在细胞信号传导中起着至关重要的作用,调节着各种生理过程。GPCRs的异常表达和突变与几种类型的癌症有关,影响肿瘤的发生、进展和免疫反应。在这篇综述中,我们概述了最近关于GPCR参与癌症的研究,并讨论了支持GPCR突变是癌症司机还是乘客的证据。在一些高度保守的结构基序中,GPCR突变的积累以及gi偶联GPCR与G蛋白亚单位α S (GNAS)激活突变之间的互斥性表明它们在癌症中的潜在驱动作用。然而,GPCR信号网络的功能冗余以及GPCR突变的广泛但低频率分布表明,它们可能更像是乘客。GPCR药物发现的未来取决于克服与数据可用性相关的挑战,以及使用多组学方法将GPCR研究与更广泛的癌症研究相结合。
期刊介绍:
The British Journal of Pharmacology (BJP) is a biomedical science journal offering comprehensive international coverage of experimental and translational pharmacology. It publishes original research, authoritative reviews, mini reviews, systematic reviews, meta-analyses, databases, letters to the Editor, and commentaries.
Review articles, databases, systematic reviews, and meta-analyses are typically commissioned, but unsolicited contributions are also considered, either as standalone papers or part of themed issues.
In addition to basic science research, BJP features translational pharmacology research, including proof-of-concept and early mechanistic studies in humans. While it generally does not publish first-in-man phase I studies or phase IIb, III, or IV studies, exceptions may be made under certain circumstances, particularly if results are combined with preclinical studies.